Health and economic benefits of an accelerated program of research to combat global infectious diseases.
出版信息
CMAJ. 2004 Nov 9;171(10):1203-8. doi: 10.1503/cmaj.1041634.
Abstract
摘要
相似文献
1
Health and economic benefits of an accelerated program of research to combat global infectious diseases.
CMAJ. 2004 Nov 9;171(10):1203-8. doi: 10.1503/cmaj.1041634.
2
TDR: (back) making a difference.
PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2531. doi: 10.1371/journal.pntd.0002531. eCollection 2014.
3
The need for global action against multidrug-resistant tuberculosis.
JAMA. 1999 Jun 9;281(22):2138-40. doi: 10.1001/jama.281.22.2138.
4
Cost-effectiveness research on preventive interventions: a survey of the publications in 2008.
Eur J Public Health. 2011 Apr;21(2):260-4. doi: 10.1093/eurpub/ckq069. Epub 2010 Jun 9.
5
Economic evaluation of programmes aiming at eradicating infectious diseases.
Health Policy. 1998 Jul;45(1):69-79. doi: 10.1016/s0168-8510(98)00032-3.
6
Economic Incentives in the Socially Optimal Management of Infectious Disease: When [Formula: see text] is Not Enough.
Ecohealth. 2018 Jun;15(2):274-289. doi: 10.1007/s10393-017-1270-9. Epub 2017 Sep 29.
7
Communicable diseases in the South-East Asia Region of the World Health Organization: towards a more effective response.
Bull World Health Organ. 2010 Mar;88(3):199-205. doi: 10.2471/BLT.09.065540.
8
Neurological disease on the global agenda.
Ann Neurol. 2008 Jul;64(1):A11-2. doi: 10.1002/ana.21477.
9
Low-income countries: where are we going with TB-HIV in 2009?
Int J Tuberc Lung Dis. 2009 Jul;13(7):797-8.
10
Global health, personal action.
Clin Infect Dis. 2004 Mar 15;38(6):879-80. doi: 10.1086/382085. Epub 2004 Feb 26.
引用本文的文献
1
Promoting equitable global health research: a policy analysis of the Canadian funding landscape.
Health Res Policy Syst. 2017 Aug 29;15(1):72. doi: 10.1186/s12961-017-0236-2.
2
Reliable direct measurement of causes of death in low- and middle-income countries.
BMC Med. 2014 Feb 4;12:19. doi: 10.1186/1741-7015-12-19.
3
Poverty and chronic diseases in Asia: challenges and opportunities.
CMAJ. 2007 Oct 23;177(9):1059-62. doi: 10.1503/cmaj.071275.
4
Prospective study of one million deaths in India: rationale, design, and validation results.
PLoS Med. 2006 Feb;3(2):e18. doi: 10.1371/journal.pmed.0030018. Epub 2005 Dec 20.
5
Global IDEA.
CMAJ. 2005 Jun 7;172(12):1538. doi: 10.1503/cmaj.1041726.
6
Global IDEA.
CMAJ. 2005 Jun 7;172(12):1537-8; author reply 1538-9. doi: 10.1503/cmaj.1041727.
7
Global failures.
CMAJ. 2004 Nov 9;171(10):1141, 1143. doi: 10.1503/cmaj.1041635.
本文引用的文献
1
How beneficent is the market? A look at the modern history of mortality.
Eur Rev Econ Hist. 1999;3(3):257-94. doi: 10.1017/s1361491699000131.
2
Innovation and challenges in funding rapid research responses to emerging infectious diseases: Lessons learned from the outbreak of severe acute respiratory syndrome.
Can J Infect Dis Med Microbiol. 2004 May;15(3):167-70. doi: 10.1155/2004/925872.
3
Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15.
4
High resistance to antiretroviral drugs: the Indian experience.
Int J STD AIDS. 2004 Mar;15(3):173-7. doi: 10.1258/095646204322916614.
5
Medical journals and global medicine.
CMAJ. 2004 Jan 6;170(1):65.
6
Are we ready for pandemic influenza?
Science. 2003 Nov 28;302(5650):1519-22. doi: 10.1126/science.1090350.
7
Public health. Grand Challenges in Global Health.
Science. 2003 Oct 17;302(5644):398-9. doi: 10.1126/science.1091769.
8
Medicine. The need for a global HIV vaccine enterprise.
Science. 2003 Jun 27;300(5628):2036-9. doi: 10.1126/science.1086916.
9
The Genome sequence of the SARS-associated coronavirus.
Science. 2003 May 30;300(5624):1399-404. doi: 10.1126/science.1085953. Epub 2003 May 1.
10
The mosquito genome: perspectives and possibilities.
Trends Parasitol. 2003 Mar;19(3):103-5. doi: 10.1016/s1471-4922(03)00021-7.
Zotero 插件